enadenotucirev

A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus.

enadenotucirev, 1402042-02-7, coload1 oncolytic virus, enad, coload1, chimeric oncolytic adenovirus ad3/ad11p containing two deletions in the viral genome in the e3 region (2444 bp) and in the e4 region (24 bp) and 197 non-homologous nucleotides in the e2b region, coload1 oncolytic virus, chimeric ad11p/ad3 oncolytic virus, coload-1

Immunotherapies

C113786